Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | May 17, 2024
Product Development
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | May 4, 2023
Finance
May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round
Plus: Big gain for ImmunoGen as Elahere hits mark in confirmatory study and updates from Cowen, Longwood, Morphic, Arthex and Dianthus
BioCentury | Nov 7, 2022
Finance
With Phase III looming, Enavate leads $118M round for Moulder’s Zenas
Patient Square-backed vehicle leads round, with trial in IgG4-related diseases imminent for lead program
BioCentury | May 3, 2022
Emerging Company Profile
Dianthus banks $121M for engineered complement mAbs
Moulder-backed company’s first program, a potential challenger for Sanofi, moves toward clinic
BioCentury | Feb 1, 2022
Data Byte
At least seven PDUFA dates on deck in February
Five submissions under FDA priority review
BioCentury | Jun 11, 2021
Product Development
June 11 Quick Takes: First-day bump for Janux; plus Vertex-CRISPR, Curis, Precigen and more
Demand for shares of Janux Therapeutics Inc. (NASDAQ:JANX) was strong enough to lift shares 48% to $25.15 in its first day of trading after the preclinical oncology company priced an upsized number of
BioCentury | Nov 14, 2020
Product Development
Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos
Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in
BioCentury | Nov 13, 2020
Emerging Company Profile
Kira: overcoming the complexities of complement
Emerging Company Profile: Kira debuts with Beddingfield as CEO, three programs slated to enter clinic over 18 months
BioCentury | May 19, 2020
Product Development
May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV
Items per page:
1 - 10 of 29